A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Wang, Zhenzhen
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Li, Zhenhua
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Shi, Weiwei
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Zhu, Dashuai
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Hu, Shiqi
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Dinh, Phuong-Uyen C.
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Cheng, Ke
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
Abstract
  • The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
License
  • Attribution 4.0 International
Journal title
  • Science Advances
Journal volume
  • 9
Journal issue
  • 25
Page start
  • eabo4100
Language
  • English
Version
  • Publisher
ISSN
  • 2375-2548

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details sciadv.abo4100.pdf 2023-07-06 Public Download